Studies of the reaction of 2-formylpyridine thiosemicarbazone and its iron and copper complexes with biological systems.
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism*; D001202:Ascitic Fluid / Q000378:metabolism; D055598:Chemical Phenomena; D002621:Chemistry; D003300:Copper / Q000097:blood / Q000378:metabolism*; D004355:Drug Stability; D005293:Ferritins / Q000378:metabolism; D006454:Hemoglobins / Q000378:metabolism; D006736:Horses; D006801:Humans; D007502:Iron Chelating Agents / Q000097:blood / Q000378:metabolism*; D008024:Ligands; D051379:Mice; D009211:Myoglobin / Q000378:metabolism; D010084:Oxidation-Reduction; D011725:Pyridines / Q000097:blood / Q000378:metabolism*; D012262:Ribonucleoside Diphosphate Reductase / Q000378:metabolism; D013882:Thiosemicarbazones / Q000097:blood / Q000378:metabolism*; D014907:Whales
D000970:Antineoplastic Agents; D006454:Hemoglobins; D007502:Iron Chelating Agents; D008024:Ligands; D009211:Myoglobin; D011725:Pyridines; D013882:Thiosemicarbazones; C013996:2-formylpyridine thiosemicarbazone; D003300:Copper; D005293:Ferritins; D012262:Ribonucleoside Diphosphate Reductase